R&D projects in in vitro ADME-Tox

 

 

MIPDILIMIP-DILI: KaLy-Cell is involved in MIP-DILI, an IMI/EPFIA funded consortium of 26 participants from the pharmaceutical industry, SMEs and academic institutions which aim is to address a better predictive test of Drug Induced Liver Injury (DILI), a major health problem with broad implications for patients, health care professionals, the pharmaceutical industry and drug regulatory agencies. MIP-DILI is a five-year project, has total budget of €32.4 million and was launched on the 29th of February 2012.

 

 

  

 

 

 

 

 

 

Image associée

 

Since October 2015, KaLy-Cell is involved with the German SME HepaCult in the collaborative Eurotransbio Project HepaCells: “Supply of high quality non-parenchymal hepatic cells to improve the prediction of hepatotoxicity assays”.

 

 

 

 

http://www.ipco-alsace.fr/wp-content/uploads/2014/09/46498.jpgSince March 2017, KaLy-Cell is involved, together with Karolinska institutet an the Eurostars’ Project E! 11034 Cryosphere: 3D co-cultures of human parenchymal and non prenchymal cells  from the same liver; Prediction of drug-induced liver injury.

For more information

Contact us

Register for our
HepatAlert notifications
for fresh or cryoplateable hepatocytes.

Request a quote!

Contact us

We look forward to
helping you find the best
solution for your
compound development
program.